Casimir is a Contract Research Organization (CRO) that develops novel outcomes for decentralized and hybrid trials in order to better understand disease progression and treatment benefit.
At Casimir, we engage patient communities as partners in research, starting every project from the patient perspective and taking new approaches to understanding and documenting disease progression and treatment benefit.
Whether you’re preclinical or post-marketing, Casimir designs and runs rigorous decentralized and hybrid studies designed to address the needs of regulators, payers and patients. We focus on getting to the truth of a disorder and adapting or developing the tools necessary to truly understand disease progression and treatment benefit.
In heterogeneous rare disease, disease-specific knowledge and nuance matters. We get to the heart of patient experience through qualitative interview projects developed in coordination with the patient community and KOLs. These projects capture insights into the ways in which treatments work.
Too often, studies fail because of poor endpoint selection or design. Casimir starts from the patient perspective and engages stakeholders including KOLs and regulators in order to develop new methods of capturing and quantifying change.